^
    1m
    Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, National Cancer Institute (NCI)
    New P1 trial • Tumor mutational burden • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    IDH wild-type • IDH1 R132
    |
    Libtayo (cemiplimab-rwlc) • Actimab-A (lintuzumab-Ac225) • Zamyl (lintuzumab)
    2ms
    Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=2, Completed, Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting --> Completed | N=102 --> 2
    Trial completion • Enrollment change • First-in-human
    |
    CD33 (CD33 Molecule)
    |
    CD33 positive
    |
    cytarabine • fludarabine IV • CD33/CLL1 dual CAR-NK cell • Super NK cell therapy
    3ms
    A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms (clinicaltrials.gov)
    P1, N=100, Recruiting, Janssen Research & Development, LLC | Trial completion date: Aug 2028 --> Jan 2028
    Trial completion date • First-in-human
    10ms
    Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=45, Terminated, Celgene | N=80 --> 45 | Active, not recruiting --> Terminated; Business objectives have changed
    Enrollment change • Trial termination
    1year
    Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=80, Active, not recruiting, Celgene | Recruiting --> Active, not recruiting
    Enrollment closed
    1year
    STING activation improves T-cell-engaging immunotherapy for acute myeloid leukemia. (PubMed, Blood)
    We established a key role for IFNγ in AMG 330-mediated cytotoxicity against AML cells, and in rendering AML cells responsive to STING agonism. Here, we propose to improve the efficacy of CD33-targeting BsAbs by combining them with a STING agonist.
    Journal
    |
    IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD33 (CD33 Molecule) • STING (stimulator of interferon response cGAMP interactor 1)
    |
    Actimmune (interferon gamma-1 b) • eluvixtamab (AMG 330)
    1year
    HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML (clinicaltrials.gov)
    P1, N=45, Recruiting, Masonic Cancer Center, University of Minnesota | Trial completion date: Nov 2029 --> Oct 2027 | Trial primary completion date: Nov 2028 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    GTB-3650
    over1year
    HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML (clinicaltrials.gov)
    P1, N=45, Recruiting, Masonic Cancer Center, University of Minnesota | Not yet recruiting --> Recruiting
    Enrollment open • Trispecific
    |
    GTB-3650
    over1year
    Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=3, Terminated, Institute of Hematology & Blood Diseases Hospital, China | N=18 --> 3 | Recruiting --> Terminated; It did not reach the expected results of clinical trial
    Enrollment change • Trial termination
    |
    CD33 (CD33 Molecule)
    |
    CD33 positive
    |
    cytarabine • fludarabine IV • QN-023a
    over1year
    HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML (clinicaltrials.gov)
    P1, N=45, Not yet recruiting, Masonic Cancer Center, University of Minnesota | Initiation date: Oct 2024 --> Jan 2025
    Trial initiation date • Trispecific
    |
    GTB-3650
    over1year
    HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML (clinicaltrials.gov)
    P1, N=45, Not yet recruiting, Masonic Cancer Center, University of Minnesota
    New P1 trial
    |
    GTB-3650
    over1year
    89Zr-immunoPET-guided selection of a CD33xIL15 fusion protein optimized for antitumor immune cell activation and in vivo tumour retention in acute myeloid leukaemia. (PubMed, Eur J Nucl Med Mol Imaging)
    This work demonstrates that CD33xIL15 fusion proteins are capable of targeting leukemic cells and stimulating local T cells in vitro and of concentrating in the tumour in AML xenografts. It also highlights the importance of 89Zr-immunoPET to guide the development and selection of tumour-targeted antibody-cytokine fusion proteins.
    Preclinical • Journal • Immune cell
    |
    CD33 (CD33 Molecule) • IL15 (Interleukin 15)
    |
    Zamyl (lintuzumab)